Cancer Pharmacology: An Illustrated Manual of Anticancer Drugs provides a one-stop guide to the essential basic and clinical science of all the effective, life-prolonging drug therapies in oncology. From traditional cytotoxic agents to targeted genomic, epigenomic, hormonal, and immunotherapeutic agents, this book covers the staggering advances in cancer pharmacology that are propelling new standards of care for common and uncommon malignancies. Beautifully illustrated throughout, each chapter contains visually engaging figures detailing the tumor microenvironment, chemical structures of agents, pharmacodynamics, pharmacokinetics, pharmacogenomic, and molecular properties of the various agents, and their mechanisms of action. As the first illustrated book of its kind, this highly visual text uses a uniform approach to each cancer drug class and agent presented in the book, and covers alkylating agents, antimetabolites, antimitotics, epigenetic modulators, hormonal agents, targeted therapies, monoclonal antibodies, immunotherapeutic agents, and much more. Flow diagrams, clinical tables, and bulleted text further explain important information pertaining to each cancer drug class including their indications, mechanisms of action, potential adverse reactions, dosing and dose adjustments, and safety monitoring. Organized in an easyto- digest format and replete with detailed images, clinical pearls, and end of chapter Q&As, this evidence-based reference presents all major classes, agents, targets, and approaches to cancer pharmacotherapy.

Whether you are a trainee, a clinical scientist, or a clinician in practice, the book is an ideal reference. It presents challenging information in an instructional way, illustrates key concepts for ease of retention, and poses tough questions so readers can problem solve potential scenarios and test their pharmacologic acumen. Written by leading experts in oncopharmacology, this first-of-its kind manual is a must have for anyone involved in the basic, translational, or clinical aspects of oncology and hematology including clinicians, pharmacists, nurses, and trainees.

Includes visual depictions of chemical structures, pharmacokinetics, pharmacodynamics, and pharmacogenomics associated with each class of agents
Describes how chemotherapy, targeted therapy, immunotherapy, and hormonal therapy work and why they are expected to work adjuvantly, neoadjuvantly, and in combination with other modalities
Over 100 highly stylized images and numerous comprehensive tables
Covers challenges related to drug development, drug approval, and regulatory issues in relation to anticancer treatments
Ashkan Emadi, MD, PhD is Professor of Medicine and Pharmacology, Associate Director of Clinical Research at the Marlene and Stewart Greenbaum Comprehensive Cancer, and Director of the Translational Genomics Laboratory at the University of Maryland School of Medicine in Baltimore, Maryland.

Judith E. Karp, MD is Professor Emerita of Oncology and Medicine at Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, in Baltimore, Maryland.



List of Contributors
Preface

PART 1. BASIC PRINCIPLES OF CANCER PHARMACOLOGY AND CLINICAL DRUG DEVELOPMENT

Chapter 1. Drug Development in Oncology 101 by Edward A. Sausville, MD, PhD and Ashkan Emadi, MD, PhD
Chapter 2. Pharmacogenomics by Molly Graveno, PharmD, BCOP
Chapter 3. Critical Components of Clinical Trials Development: From Bench to Bedside and Back by S. Percy Ivy, MD, Richard F. Little, MD, and Joshua F. Zeidner, MD
Chapter 4. Drug Development and Regulatory Considerations by Vicky Hsu, PhD, Matthew D. Thompson, PhD, MPH, Donna Przepiorka, MD, PhD, and Olanrewaju O. Okusanya, Pharm.D., MS
PART 2. CLASSICAL CYTOTOXIC AGENTS

Chapter 5. Alkylating Agents and Drugs Perturbing DNA Structure by Ashkan Emadi, MD, PhD and Edward A. Sausville, MD, PhD
Chapter 6. Pyrimidine- and Purine-based Antimetabolites, Hydroxyurea, Asparaginases by Ashkan Emadi, MD, PhD and Judith E. Karp, MD
Chapter 7. Antifolate Antimetabolites by Justin Lawson, PharmD, BCOP
Chapter 8. Antimitotics by Edward A. Sausville, MD, PhD and Ashkan Emadi, MD, PhD
PART 3. EXPLOITING CELLULAR AND EXTRACELLULAR PATHWAYS

Chapter 9. Drugs Targeting DNA Repair, Cell Cycle and Apoptosis by Mira A. Kohorst, MD and Scott H. Kaufmann, MD, PhD
Chapter 10. Epigenetic Modulators by Sergiu Pasca, MD and Lukasz P. Gondek, MD, PhD
Chapter 11. Differentiating Agents and Microenvironment by Yuya Nagai, MD, PhD and Gabriel Ghiaur, MD, PhD
PART 4. ORGAN-TARGETED APPROACHES

Chapter 12. Targeted Therapeutics (Small Molecules) by Yuchen (Jake) Liu, MD and Ashkan Emadi, MD, PhD
Chapter 13. Hormonal Therapies Alone and in Combinations for Treatment of Breast Cancer by Amy M. Fulton, PhD and Katherine H. R. Tkaczuk, MD
Chapter 14. Androgen Receptor Axis Targeting in the Treatment of Prostate Cancer by Vincent C. O. Njar, PhD, and Arif Hussain, MD
Chapter 15. Multiple Myeloma as a Paradigm for Multi-Targeted Intervention by Kathryn Maples, PharmD, BCOP and Sagar Lonial, MD
PART 5. IMMUNE-TARGETED STRATEGIES

Chapter 16. Transplant-Related Agents: Focus on Graft vs. Host Disease Prevention and Treatment by Vedran Radojcic, MD
Chapter 17. Monoclonal Antibodies Including Immunoconjugates, Antibody-Drug Conjugates, Immunoconjugates, and Cytokine-Directed Agents by Alison Duffy, PharmD, BCOP and Ciera Bernhardi, PharmD, BCOP
Chapter 18. Immunotherapeutics: Immune Checkpoint Inhibitors, Vaccines, Bispecifics, and Engineered T Cells by Mark Yarchoan, MD and Elizabeth Jaffee, MD
Index